The People's Insurance (601319.SH)'s application for issuing A-shares to specific targets accepted by the Shanghai Stock Exchange.
The People's Insurance (601319.SH) announced that on October 8, 2026, the company received the "Notice on Accepting the Application of The People's Insurance Company (Group) of China Limited, a Main Board Listed Company in Shanghai, for Issuing Securities" issued by the Shanghai Stock Exchange (the "SSE"). In accordance with relevant regulations, the SSE reviewed the prospectus and related application documents for the issuance of securities by the company, a main board listed company in Shanghai, and determined that the application documents are complete and comply with statutory requirements. The SSE decided to accept the application and conduct review in accordance with the law.
The People's Insurance (601319.SH) announced that on October 8, 2026, the company received a notice issued by the Shanghai Stock Exchange (the "SSE") regarding the acceptance of the application for securities issuance by a company listed on the SSE Main Board, PICC GROUP Co., Ltd. The SSE, in accordance with relevant regulations, reviewed the prospectus and related application documents for securities issuance by the SSE Main Board-listed company submitted by the company, and determined that the application documents are complete and comply with statutory requirements. The SSE decided to accept the application and conduct review in accordance with the law.
Related Articles
Shenwan Hongyuan Group (06806): Zhang Xi nominated as candidate for non-executive director
Jiangsu Lopal Tech. Group (02465)'s second-tier controlling subsidiary, Nanjing Lihyuan, signed a Strategic Cooperation Framework Agreement with Jiyao Tongxing.
Lepu Medical Technology (300003.SZ) subsidiary receives U.S. FDA approval for clinical trial of MWN117 injection.
Shenwan Hongyuan Group (06806): Zhang Xi nominated as candidate for non-executive director
Jiangsu Lopal Tech. Group (02465)'s second-tier controlling subsidiary, Nanjing Lihyuan, signed a Strategic Cooperation Framework Agreement with Jiyao Tongxing.
Lepu Medical Technology (300003.SZ) subsidiary receives U.S. FDA approval for clinical trial of MWN117 injection.
